Startup Pitch: EnteroBioSystems' Stem-Cell-Derived Human Mini-Intestine Organoids for Drug Testing

Co-founder and CEO Charlie Childs presents EnteroBioSystems, a startup engineering complex human intestinal organoids to replace animal models in research. The pitch covers the science behind the product, the manufacturing process, early commercial traction, funding plans, and the judges' follow-up questions.

■ Technology & Product
- How organoids are generated from reprogrammed adult stem cells collected from blood, saliva, or urine samples
- What the models contain: smooth muscle, nerves, blood vessels, immune cells, and intestinal epithelium
- Manufacturing capacity, customization, and a live demonstration of product delivery and analysis
- Comparison with competitor approaches and demonstrated organ-level functions

■ Business & Traction
- Customer base, revenue, patents, lab affiliations, and strategic investment to date
- The current funding round, planned use of capital, and capacity expansion
- Product versus service positioning, data licensing, exit considerations, and a longer-term roadmap

■ Judge Q&A
- Differentiation from other organoid platforms and from AI-driven in-silico modeling
- Potential skin organoid work, licensing strategy, and toxicity/safety applications

The content is suited to biotech investors, startup founders, pharma R&D and drug-development teams, and researchers exploring alternatives to animal testing. Viewers can gain an understanding of organoid technology, how such a platform is commercialized, and how investors evaluate a deep-tech biotech pitch.